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ABSTRACT: Tumor hypoxia contributes resistance to chemo- and
radiotherapy, while oxygenated tumors are sensitive to these
treatments. The indirect detection of hypoxic tumors is possible
by targeting carbonic anhydrase IX (CA IX), an enzyme
overexpressed in hypoxic tumors, with sulfonamide-based imaging
agents. In this study, we present the design and synthesis of novel
gallium-radiolabeled small-molecule sulfonamides targeting CA IX.
The compounds display favorable in vivo pharmacokinetics and
stability. We demonstrate that our lead compound, [68Ga]-2,
discriminates CA IX-expressing tumors in vivo in a mouse xenograft
model using positron emission tomography (PET). This compound
shows specific tumor accumulation and low uptake in blood and
clears intact to the urine. These findings were reproduced in a second study using PET/computed tomography. Small molecules
investigated to date utilizing 68Ga for preclinical CA IX imaging are scarce, and this is one of the first effective 68Ga compounds
reported for PET imaging of CA IX.
■ INTRODUCTION
Molecular imaging with positron emission tomography (PET)
has had a profound impact on primary diagnosis, management,
therapy monitoring, and prognosis in cancer; it is noninvasive
and provides personalized care to patients by informing
treatment decisions and evaluating treatment response.
Hypoxia (low oxygen concentration) is a characteristic feature
of solid tumors. Hypoxic cells co-opt adaptive mechanisms to
switch to a glycolytic metabolism, promote cell proliferation,
evade immune attack, induce angiogenesis, invade, and
metastasize.1 Tumor hypoxia is a negative prognostic factor
associated with a more aggressive phenotype, specifically with
resistance to chemo- and radiotherapy. For example, up to a 3-
fold higher radiation dose is needed to achieve the same level of
tumor cell death in hypoxic tumors as in oxygenated tumors.2
The implementation of a hypoxia-guided clinical management
strategy, such as hypoxia radiation sensitizers (e.g., nimor-
azole3) or hypoxia-specific cytotoxic therapy (e.g., TH-302;
Figure 1A),4 to those patients most likely to benefit is currently
not possible, as there is no established method in routine
clinical practice that is (i) noninvasive, (ii) routine to prepare,
and (iii) indicative of the hypoxic cell population.2 Most
current methods to detect hypoxia are invasive (e.g., require
surgery) and are subject to technical issues that cause sampling
errors.
Small-molecule molecular probes for imaging of hypoxia with
PET may be split into two broad categories: “direct” and
“indirect” imaging probes. Nitroimidazoles are direct imaging
probes for the detection of hypoxia with PET, with one
compound, 18F-fluoromisonidazole (18F-FMISO) in limited
clinical use.5 Second- and third-generation nitroimidazoles, 18F-
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FAZA and 18F-HX4, respectively, have been shown by us to
address the pharmacokinetic (PK) problems of 18F-FMISO
(slow tumor-specific accumulation and nonspecific washout),
but better probes for hypoxia are still required.5−8
A critical cellular response to hypoxia is the stabilization and
activation of the transcription factor hypoxia inducible factor-1α
(HIF-1α). HIF-1α regulates the expression of genes required
for survival under hypoxia. In principle, the gene products may
be used as targets for imaging of tumor hypoxia with indirect
probes and bypass the drawbacks associated with nitro-
imidazole probes.9 Carbonic anhydrase IX (CA IX) is one of
the most highly induced HIF-1α-responsive genes and is
proposed as the “gold standard” endogenous marker of cellular
hypoxia.10−13 CA IX expression is a negative prognostic factor
in several types of cancer.14 Additionally CA IX (over)-
expression is thought to predict the therapeutic effect of CA IX-
targeting anticancer therapies. CA IX is overexpressed and
sustained in many solid tumors, including breast, brain
(glioblastoma), clear cell renal, colorectal, head and neck,
bladder, and non-small cell lung carcinomas, but expression in
normal tissues is restricted to the stomach and gastrointestinal
tract.10,15
CA IX is a transmembrane zinc metalloenzyme that catalyzes
the reversible hydration of CO2 to give HCO3
− and H+,
enabling the tumor to regulate pH, allowing its spread and
survival.12,13,16−20 Expression of CA IX is commonly used as a
histologic marker of tissue hypoxia, with detection using M7518
or G250,21 two different monoclonal antibodies specific for CA
IX. There are several antibody- and antibody-fragment-based
imaging agents with in vivo data that indirectly target hypoxic
tumors by binding to CA IX.22,23
Our groups have shown that small-molecule sulfonamides are
able to discriminate oxygen levels in tissues and bind
preferentially to CA IX only in hypoxic cells, while CA IX-
targeting antibodies also bind upon reoxygenation.24 Therefore,
our attention has turned to small molecules to develop
radiopharmaceuticals to detect CA IX-positive tumors with
PET. To date, very few small molecules that incorporate a
primary sulfonamide functional group, which is required for
tight binding to the active site zinc in CA IX (see examples in
Figure 1), have been developed and tested for CA IX imaging
with PET in vivo.25−29 Compound [18F]U-104 proved to be
ineffective because of poor PK.28 [18F]VM4-037 was found to
be safe for use in healthy volunteers,25 but no CA IX-dependent
uptake was found in vivo.30,31 In a recent phase-II pilot study of
two patients with clear cell renal cell carcinoma (RCC) primary
tumors with this agent, uptake was observed in both healthy
and cancerous kidney as well as metastases, and CA IX
selectivity was not confirmed,32 limiting the use of this imaging
agent in RCC. The trivalent sulfonamide compounds [18F]-
AmBF3-(ABS)3 and [
18F]AmBF3-(AEBS)3 have demonstrated
imaging efficacy in vivo enabling tumor visualization with a
Figure 1. (A) Nitroimidazole hypoxia-targeted cytotoxic drug TH-302 and small-molecule nitroimidazole PET imaging agents for hypoxia: 18F-
MISO, 18F-FAZA, and 18F-HX4. (B) Small-molecule primary sulfonamides investigated in animal models for CA IX imaging with PET.25−28
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respective tumor-to-blood ratio (TBR) of 3.93 ± 1.26 or 2.88 ±
1.81 in CA IX-expressing HT-29 tumors 1 h after injection.
Interestingly, the monovalent variants showed a TBR close to
unity and hence were less effective as imaging agents.26 No
discrimination between CA IX-expressing or nonexpressing
tumors was shown, but preinjection of acetazolamide effectively
blocked uptake of [18F]AmBF3-(ABS)3 in the tumor. Recently
another series of mono-, di-, and trivalent sulfonamides based
on 68Ga-DOTA/NOTGA as the PET reporter group were
tested in a CA IX-expressing HT-29 tumor xenograft, and again
only the trivalent sulfonamide (68Ga-NOTGA-AEBSA3) had a
TBR that significantly differed from that of the controlse
controls (where test animals were first treated with
acetazolamide as a CA IX-blocking sulfonamide).27
68Ga (t1/2 = 68 min) has been used to label small molecules,
biological macromolecules, and nano- and microparticles.33 It is
a favorable positron emitter because its γ emission is negligible
and it can be produced in a 68Ge/68Ga generator, so an on-site
cyclotron is not required.34 As the parent radionuclide 68Ge has
a long half-life (t1/2 = 270.8 days), it can be stored for relatively
long periods.34 To make PET imaging with sulfonamides
suitable for eventual use in cancer patients, the purpose of the
present work is to design and synthesize novel small-molecule
68Ga-labeled imaging agents that can selectively target CA IX-
positive tumor cells in vivo. Specifically, agents with improved
PK properties, CA IX targeting, TBR, and image contrast
compared with those previously described are sought.
■ RESULTS AND DISCUSSION
Compound Design and Synthesis. Most small-molecule
CA inhibitors incorporate a primary sulfonamide functional
group, which imparts molecular recognition specificity for the
zinc in the active site of CAs but not the metals of other
metalloenzymes.29 The active site of CA IX is, however,
structurally similar to those of CA I and CA II, the major CA
isozymes within red blood cells, (CA I: 1.6 ± 2.3 mg/g of
hemoglobin (Hb); CA II: 1.8 ± 0.3 mg/g of Hb).35 As a
consequence of the binding of sulfonamide-based imaging
agents to CA I and CA II in red blood cells, increased
background signal and reduced image contrast have hampered
the efforts of others in this field.2,36,37 Our group has
contributed substantially to the development of CA inhibitors
with enhanced selectivity for CA IX over CA I and CA II in
vitro and, via extrapolation, in vivo.4 We have shown that the
different CA active sites have variable tolerance to the nature of
moieties appended to the aromatic sulfonamide CA targeting
group.38−42 This attribute allows fine-tuning of the bioactive,
physicochemical, and toxicological properties of the compound
to better target a particular CA isozyme.43 The CA IX targeting
agents of this study, compounds 1 (natGa and 67Ga) and 2
(natGa, 67Ga, and 68Ga), extend our established design
principles. These compounds are primary sulfonamides
tethered to a metal chelator, 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (DOTA), via either an intervening
aliphatic triazole linker (1) or a hydrophilic triazole poly-
(ethylene glycol) (PEG) linker (2) (Figure 2). The DOTA
macrocycle is the workhorse metal ion chelator for molecular
imaging agents, forming stable complexes with the PET
Figure 2. Target [sulfonamide]−[triazole linker]−[DOTA] compounds for use as CA IX imaging agents.
Scheme 1. Synthesis of natGa-1a
aReagents and conditions: (i) bromoacetyl bromide (3.3 equiv), 1.0 M aqueous NaOH (3 equiv), DCM, rt, 18 h; (ii) 5 (1.0 equiv), CuSO4 (0.05
equiv), sodium ascorbate (0.1 equiv), TBTA (0.05 equiv), 2:1 DMSO/H2O, 45 °C, 3 h; (iii) 7 (1.2 equiv), K2CO3 (1.2 equiv), anhydrous MeCN, rt,
18 h; (iv) 1:1 TFA/DCM, rt, 18 h; (v) Ga(NO3)3·xH2O (1.1 equiv), H2O, 80 °C, 2−4 h.
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imaging isotope 68Ga.44 68Ga is becoming a relevant isotope for
routine clinical examinations, with 68Ga PET imaging agents
such as 68Ga-DOTATATE and 68Ga-HBED-PSMA in clinical
use.45,46 67Ga is a common radionuclide for use with single-
photon-emission computed tomography (SPECT). The most
widely used application is of 67Ga-citrate for inflammation and
infection imaging. The relatively long half-life (t1/2 = 3.26 days)
makes 67Ga a useful tool for the assessment of key parameters
of gallium-based radiopharmaceuticals, including radiochemical
stability, metabolic stability, and plasma protein binding, and
this in turn informs subsequent decisions on in vivo protocols.
The preparation of 67Ga complexes also permits the
optimization of radiolabeling conditions, purification method-
ology, and reformulation procedures prior to using the shorter-
half-life PET radionuclide 68Ga. We first synthesized the “cold”
compounds, natGa-1 and natGa-2, followed by the corresponding
radiolabeled compounds [67Ga]-1 and [67Ga]-2 to establish
optimized radiolabeling conditions. [68Ga]-2 was selected as the
target compound for in vivo PET imaging studies.
The compound design as [sulfonamide]−[variable linker]−
[DOTA] is deliberately modular. This enables a straightforward
synthesis using copper-catalyzed azide−alkyne cycloaddition
(CuAAC), or “click chemistry”, to combine the components.
CuAAC is one of the most accomplished reactions for
combining groups to pool their individual properties into a
single molecule.47 The biopharmaceutical stability of the
resulting triazole is favorable, as it is resistant to acidic, basic,
reductive, and oxidative conditions in addition to enzymatic
degradation.48 Scaffold 2 employs a tetraethylene glycol linker,
which is a shortened PEG chain with good biopharmaceutical
properties, polarity, and water solubility, aiding the eventual
formulation.49 The PEG-based linker was additionally selected
to enhance the likelihood that the agents would have improved
specificity for CA IX. The increased polarity reduces plasma
protein binding and membrane permeability and thus may
lessen the off-target binding to CA I and CA II in red blood
cells.50 A previous generation of DOTA-based scaffolds were
designed by Rami and co-workers, but to the best of our
knowledge, these were not radiolabeled or evaluated as CA IX
imaging agents in vivo.51,52
The target compounds 1 and 2 are synthesized from three
modular components, [sulfonamide], [linker], and [DOTA],
with incorporation of the gallium cation as the final step
(Schemes 1 and 2). The synthesis of the [sulfonamide]
component, 4-ethynylbenzenesulfonamide (5), has been
described previously.53 The [linker] components, 4 and 11,
were designed with orthogonal end groups. An azide facilitates
the reaction with 5 via CuAAC, while the bromide provides an
orthogonal leaving group facilitating the SN2 substitution
reaction with the [DOTA] component 7. Linkers 4 and 11
were prepared by reaction of bromoacetyl bromide (3.3 equiv)
with amino azides 354 and 10, respectively.55 The [sulfona-
mide] component 5 and [linker] components 4 and 11 were
subjected to CuSO4 (0.01−0.05 equiv), sodium ascorbate (0.1
equiv), and TBTA (0.01−0.05 equiv) to generate 6 and 12,
respectively. The removal of excess copper ions from 6 and 12
was achieved by a solid EDTA chase or by washing the organic
phases with EDTA (1.0 M) in ammonium hydroxide (28.0−
30.0%, NH3 basis) solution. The [DOTA] component 7 was
prepared from commercially available cyclen as described by
Scheme 2. Synthesis of natGa-2a
aReagents and conditions: (i) bromoacetyl bromide (3.3 equiv), NaOH (1.0 M, 2 equiv), DCM, rt, 18 h; (ii) 5 (1.0 equiv), CuSO4 (0.01 equiv),
sodium ascorbate (0.1 equiv), TBTA (0.01 equiv), 2:1 DMSO/H2O, 30 °C, 18 h; (iii) 7 (1.2 equiv), K2CO3 (1.3 equiv), anhydrous MeCN, 60 °C, 3
h; (iv) 1:1 TFA/DCM, rt, 18 h; (v) Ga(NO3)3·xH2O (1.1 equiv), H2O, 80 °C, 2−4 h.




compd hCA I hCA II hCA IX hCA XII CA I/CA IX CA II/CA IX CA XII/CA IX
acetazolamided 250 12 25 n/a 10 0.48 n/a
natGa-1 387 72.5 84.7 59.6 4.57 0.85 0.70
natGa-2 169 78.3 63.1 56.8 2.67 1.24 0.90
aErrors were in the range of ±5% of the reported value, from three determinations. bMeasured using a stopped-flow assay that monitors the
physiological reaction (CA-catalyzed hydration of CO2).
57,58 cSelectivity is determined by the ratio of Ki values for CA isozymes I, II, and XII relative
to CA IX. dLiterature acetazolamide values.59
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Prashun et al.56 SN2 substitution of 6 and 12 with 7 using
anhydrous conditions gave the tBu-protected compounds 8 and
13 in reasonable yields. Treatment of compounds 8 and 13
with either neat formic acid or 1:1 TFA/DCM removed the tBu
protecting groups to provide the nonmetalated precursor
compounds 9 and 14 in high yield. Next, the target natGa
complexes, natGa-1 and natGa-2, were prepared in quantitative
yield from 9 and 14 using Ga(NO3)3·xH2O in H2O with the
pH adjusted to pH 4.5 with 1.0 M HCl or 1.0 M KOH.
Compounds 9 and 14 were purified by reversed-phase HPLC
(RP-HPLC) prior to biological evaluation and radiolabeling
with 67Ga and/or 68Ga.
Carbonic Anhydrase Binding. The CA binding data for
natGa-1, natGa-2, and the reference CA inhibitor acetazolamide
were measured for the cancer-associated CA isozymes CA IX
and XII and the off-target CA isozymes CA I and II.
Compounds natGa-1 and natGa-2 have low affinity for CA I
but bind equally well to CA II, CA IX, and CA XII (Ki range
59.6−84.7 nM) (Table 1). Binding to CA II supports the
significance and importance of designing probes to have
reduced cell-membrane permeability, as this limits access of the
probes to the intracellular CA II.
Radiochemistry. Compounds 9 and 14 were successfully
radiolabeled with 67Ga under standard conditions (0.1 M
sodium acetate, pH 4.5, 10 min, 95 °C). To test the robustness
of the radiolabeling method developed, the compound amount
was progressively reduced from 10 to 1 nmol and the
radiochemical yield quantified by RP-HPLC (Table 2). It was
shown that 9 was successfully radiolabeled (to give [67Ga]-1)
down to 2 nmol of compound (98%) but at 1 nmol, only 61%
radiolabeling was achieved. However, 14 was radiolabeled
efficiently (to give [67Ga]-2) down to 1 nmol of compound
(>99%). Purification of the radiolabeled products was carried
out using either RP-HPLC or rapid reversed phase C-18 solid-
phase extraction (SPE). Both [67Ga]-1 and [67Ga]-2 were
reformulated into phosphate-buffered saline (PBS).
Compound 14 was radiolabeled with 68Ga (200−800 MBq,
eluted from a 68Ge/68Ga generator (IDB Holland, Baarle-
Nassau, The Netherlands) in about 1 mL of 0.6 M HCl), in 400
μL of 3.0 M sodium acetate or ammonium acetate (pH 4.3, 10
min, 99 °C) in high radiochemical purity (>95%) as
determined by radio-RP-HPLC (Inertsil ODS C18, 5 μM, 4.6
mm × 250 mm, 100:0 → 0:100 H2O + 0.1% TFA/MeCN +
0.1% TFA, 1.0 mL/min).
Biopharmaceutical Properties. The stability of the 67Ga-
radiolabeled compounds [67Ga]-1 and [67Ga]-2 was examined
in PBS (pH 7.4). The compounds were found to be stable, with
≥95% of the parent compounds remaining after 18 h of
incubation at 37.5 °C and ≥90% after 96 h of incubation. The
protein binding of [67Ga]-1 and [67Ga]-2 to human serum was
minimal (<7%, n = 3) after 48 h. [67Ga]-2 exhibited favorable
radiochemical purity (data not shown), good stability, and good
preliminary physicochemical properties. Hence, additional
biopharmaceutical properties of cold natGa-2 were assessed
(Table 3); by extrapolation, these properties should reflect
those expected for the radiolabeled analogue [68Ga]-2. The in
vitro metabolic stability of compound natGa-2 in mouse liver
microsomes was measured in the presence and absence of
NADPH, the cofactor required for oxidative metabolism by
cytochrome P450s. Compound natGa-2 exhibited minimal
microsomal degradation (t1/2 > 247 min), and it is expected
that compound natGa-2 is subject to low hepatic clearance in
vivo. The in vitro intrinsic clearance of natGa-2 was low (<7 μL
min−1 (mg of protein)−1). The in vitro membrane permeability
(Papp) of
natGa-2 in the Caco-2 cell model (pH 7.4) was
measured. natGa-2 was not detected in the Caco-2 assay
acceptor chamber, while good mass balance (92% ± 6%)
confirmed minimal retention of the compound within the cell
monolayer and minimal nonspecific adsorption. The exper-
imental value measured, Papp < 0.7 cm/s, indicates that
natGa-2
has very low cell membrane permeability. The stability and
extent of plasma protein binding of natGa-2 in mouse plasma
was analyzed. The measured concentration of natGa-2 in mouse
plasma samples (37 °C) quenched at 2 min was unchanged.
However, at 10 min the concentration of natGa-2 had dropped
but then remained steady over the remainder of the 4 h
incubation. Plasma protein binding of natGa-2 was low (39%)
following 4 h of incubation. The cytotoxicity and cell viability of
natGa-2 were tested via a standard methyl thiazolyl tetrazolium
assay, with no toxicity observed up to 1 mM natGa-2 in
normoxia (data not shown). Collectively, these additional
properties of natGa-2 are indicative of a safe, well-tolerated
compound with physicochemical properties suited to prefer-
ential targeting of CA IX over intracellular CAs and hence a
favorable TBR of the corresponding 68Ga compound.
Small-Animal PET and PET/CT Imaging Studies. Our
lead compound, [68Ga]-2, was chosen for follow-up in vivo
PET studies and was injected intravenously into mice bearing
HCT116 tumors with high or low CA IX expression to assess
the selectivity of uptake using PET. The efficiency of CA IX
genetic silencing was determined by Western blot analysis and
immunofluorescence. In agreement with previous studies,60,61
CA IX levels were significantly lower in CA IX-knockdown
tumors than in CA IX-expressing tumors (Figure 3A,B).
Table 2. Radiochemical Yields of [67Ga]-1 and [67Ga]-2 at
Varying Compound Concentrationsa
radiochemical yield (%)b
amount of compd (nmol) 9 → [67Ga]-1 14 → [67Ga]-2
25 100c 100




aReaction conditions: Compound 9 or 14 (1 mM in water), sodium
acetate (0.1 M, to pH 4.5), 67GaCl3 (18−21 MBq in 0.1 M HCl), 95
°C, 10 min. bAs determined by RP-HPLC (conditions available in the
Supporting Information). cLabeling in HEPES buffer proceeded with
>99% radiochemical yield. d±standard deviation based on two
radiolabeling experiments.

















>247 <7 <0.13 <0.7 39%
aThe metabolic stability parameters for compound natGa-2 are based
on NADPH-dependent degradation profiles in mouse liver micro-
somes. In vitro CLint is the intrinsic clearance value.
bPredicted in vivo
hepatic extraction ratio (EH).
cPapp = apparent permeability across
Caco-2 monolayers. dAverage of duplicate determinations.
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Additionally, as determined by immunofluorescence staining,
membranous CA IX expression was colocalized with the
exogenous hypoxia marker pimonidazole in CA IX-expressing
tumors, whereas in CA IX-knockdown tumors very low or no
CA IX expression was present (Figure 3C). This confirms
efficient CA IX knockdown and thus CA IX-dependent uptake
of [68Ga]-2.
In order to determine the optimal imaging time point, μPET
scans were acquired hourly from 1 to 4 h post injection (h p.i.)
of [68Ga]-2. Tumor uptake in the CA IX-expressing model was
clearly observed and found to be highest at 1 h p.i. (Figure 4A).
This time point was selected for all of the subsequent
experiments. Additionally, it was found that the agent was
rapidly excreted renally, as observed by the high presence of the
agent in the kidneys and bladder. Mass spectrometry analysis of
the urine confirmed that the compound was cleared without
metabolism.
To assess the compound selectivity, uptake was compared
between mice with either CA IX-expressing or CA IX-
knockdown tumors. Although CA IX-knockdown tumors
tend to grow slower than their CA IX-expressing counter-
parts,61 the tumor volumes at the time of scans were not
statistically different (P = 0.422) between the two groups (315
± 104 and 277 ± 63 mm3 for CA IX-expressing and CA IX-
Figure 3. CA IX expression in mice bearing CA IX-expressing (shNT) or CA IX-knockdown (shCA IX) tumors. (A) Western blot showing CA IX
protein levels in representative samples. (B) Quantification of CA IX protein levels as determined by Western blot for all shNT and shCA IX tumors.
(C) Immunofluorescence staining of CA IX (red) and the hypoxia marker pimonidazole (green). Right-side images are magnifications of areas
within the white rectangles in the left-side images. “n” indicates necrotic areas.
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knockdown tumors, respectively). The TBR was significantly
higher (P < 0.01) in mice bearing CA IX-expressing tumors
(3.87 ± 1.34) compared with mice bearing CA IX-knockdown
tumors (1.99 ± 0.99) (Figure 4B,C). Uptake of [68Ga]-2 was
therefore found to be CA IX-dependent. However, the lack of
anatomical information in the acquired PET images prompted
us to verify colocalization with computed tomography (CT).
Therefore, the experiments were repeated to include CT scans,
enabling better tumor delineation in the fused PET/CT images
and more clearly confirming the localization of the agent in the
tumor. Again the tumor volumes at the time of scans were not
statistically different (P = 0.071) between the two groups (492
± 390 and 125 ± 44 mm3 for CA IX-expressing and CA IX-
knockdown tumors, respectively). Similar to the first experi-
ment, the TBR was significantly higher (P < 0.01) in mice
bearing CA IX-expressing tumors (2.36 ± 0.424) than in mice
bearing CA IX-knockdown tumors (1.30 ± 0.350) (Figure
5A,B). Autoradiography analysis of tumor sections supported
the μPET results, showing a higher signal intensity relative to
injected dose (ID) in CA IX-expressing tumors (9.12 × 10−7 ±
7.25 × 10−7) compared with CA IX-knockdown tumors (3.84
× 10−7 ± 1.53 × 10−7) (Figure 5C). Low uptake of [68Ga]-2
was also observed in the CA IX-knockdown model, which can
be explained by residual CA IX expression in these tumors.
Nevertheless, the significantly higher uptake of [68Ga]-2 in
tumors with high CA IX expression confirms the selectivity of
this imaging compound.
■ CONCLUSION
This study provides the first evidence of noninvasive, specific
detection of CA IX in vivo using a CA IX-targeting small-
molecule PET radiotracer, [68Ga]-2. The synthesis of the
unlabeled precursor of [68Ga]-2 (compound 14) and the
radiochemistry to introduce 68Ga were straightforward,
proceeded in good yields, and were reproducible, and the
biopharmaceutical properties were favorable. This study is a
promising step toward a new predictive tool that will enable
testing of the potential of CA IX expression as a biomarker for
selection of patients eligible for CA IX-targeting anticancer
therapies.
■ EXPERIMENTAL SECTION
ChemistryGeneral Methods. All of the starting materials and
reagents were purchased from commercial suppliers. Where specified,
solvents were available commercially dried or were dried prior to use.
Reactions took place open to the atmosphere unless otherwise
specified. Reaction progress was monitored by thin-layer chromatog-
raphy (TLC) using silica gel 60 F254 plates with detection by short-
wave UV fluorescence (λ = 254 nm) and staining with ninhydrin (1 g
of ninhydrin, 200 mL of EtOH, 8 mL of acetic acid), KMnO4 (0.75 g
of KMnO4, 5 g of K2CO3, 75 mg of NaOH, 100 mL of H2O), or
vanillin stain (5 g of vanillin in an 87:10.2:2.8 EtOH/H2O/H2SO4
mixture with subsequent heating); by TLC using RP-18 silica gel 60
F254 plates with detection by short-wave UV fluorescence; or by high-
performance liquid chromatography (HPLC) on an Agilent 1100
Figure 4. [68Ga]-2 uptake in mice bearing CA IX-expressing (shNT)
or CA IX-knockdown (shCA IX) tumors. (A) Representative μPET
scans at 1−4 h p.i. in a shNT-tumor bearing mouse. (B)
Representative μPET scans at 1 h p.i. (C) TBRs of [68Ga]-2 uptake
determined from PET scans of shNT-tumor bearing mice (n = 11)
and shCA IX-tumor bearing mice (n = 6). **, P < 0.01.
Figure 5. [68Ga]-2 uptake in mice bearing CA IX-expressing (shNT) or CA IX-knockdown (shCA IX) tumors. (A) Representative μPET/CT fusion
images at 1 h p.i. (B) TBRs of [68Ga]-2 uptake determined from PET scans of shNT-tumor bearing mice (n = 4) and shCA IX-tumor bearing mice
(n = 5). **, P < 0.01. (C) Signal intensity relative to injected dose (ID) as determined by autoradiography analysis of tumor sections from shNT-
tumor bearing mice (n = 6) and shCA IX-tumor bearing mice (n = 6).
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system using a Thermo Betasil C18 column (150 mm × 4.6 mm, 5
μm) and a gradient method of 95:5 → 5:95 H2O (+0.1% TFA)/
acetonitrile (+0.1% TFA) over 10 min at a flow rate of 1 mL/min.
Silica gel flash chromatography was performed using silica gel 60 Å
(230−400 mesh). NMR (1H, 13C{1H}, 1H−1H gCOSY, and HSQC)
spectra were recorded on either a 400 or 500 MHz spectrometer at 30
°C. 1H NMR spectra were referenced to the residual solvent peak
(CDCl3, 7.26 ppm; DMSO-d6, 2.50 ppm).
13C NMR spectra were
referenced to the internal solvent (CDCl3, 77.0 ppm; DMSO-d6, 39.5
ppm). Multiplicity is indicated as follows: s (singlet), d (doublet), t
(triplet), q (quartet), quint (quintuplet), m (multiplet), dd (doublet of
doublets), ddd (doublet of doublets of doublets), b (broad). Coupling
constants (J) are reported in hertz. Mestrenova 6.1 software was used
for NMR analysis. Melting points are uncorrected. Mass spectra (low-
and high-resolution) were recorded using electrospray as the
ionization technique in positive-ion and/or negative-ion mode as
stated. The purities of all final compounds (8, 9, natGa-1, and natGa-2)
were ≥95% as determined by HPLC with UV detection. Compounds
3, 4, 5, 7, and 10 were synthesized as described elsewhere, with
characterization in agreement with the literature.53,54,56,62−65 The atom
labeling of DOTA compounds used for NMR assignments is shown in
Scheme 3.
ChemistrySynthesis Methods. General Procedure 1: Syn-
thesis of Brominated [linker] Components. The amino azide
precursor (1 equiv) was suspended in a biphasic DCM/NaOH(aq)
solution (2:1, 2−3 equiv of NaOH) and cooled to 0 °C. Bromoacetyl
bromide (3 equiv) was added dropwise to the DCM layer. The
solution was then stirred vigorously overnight at rt. The reaction
mixture was diluted with DCM and H2O, and the aqueous fraction was
extracted with DCM (2 × 50 mL). The organic fractions were
combined and washed with 50 mM Na2CO3 (3 × 50 mL), dried with
MgSO4, filtered, and concentrated. The crude compound was
sufficiently pure and used crude in the next step.
General Procedure 2: Addition of “Cold” Ga. The parent
compound (9 or 14, 1 equiv) was suspended in H2O, and excess
Ga(NO3)3·xH2O(aq) was added. The pH of the reaction mixture was
adjusted to ∼4.5 using KOH (1.0 M) or HCl (1.0 M). The reaction
mixture was heated at 80 °C, and the pH was monitored and adjusted
accordingly to maintain pH 4.5. The reaction mixture stabilized after
∼2 h. Reaction progress was monitored by LC−MS. Products were
purified by RP-18 flash column chromatography (H2O/MeOH 100:0
→ 5:95), and the solvent was removed in vacuo, leaving a hygroscopic
solid.
N-(3-Azidopropyl)-2-bromoacetamide (4). The title compound
was synthesized from 3-azido-1-propanamine HCl salt (3) (1.5 g, 11
mmol) and NaOH (2 equiv) using general procedure 1 and isolated as
a yellow oil (1.9 g, 78%). Rf 0.13 (90:10 DCM/MeOH).
1H NMR
(500 MHz, CDCl3): δH 6.72 (br s, 1H, NH), 3.88 (s, 2H, βCH2),
3.40−3.36 (m, 4H, γCH2, εCH2), 1.82 (quint, 2H, J = 6.60 Hz, δCH2).
13C NMR (125 MHz, CDCl3): δC 165.8 (αCO), 49.5 (εCH2 or
γCH2), 38.1 (εCH2 or γCH2), 29.3 (βCH2), 28.6 (δCH2). LRMS
(ESI−): m/z = 221, 219 [M − H; 81Br, 79Br]−. HRMS (ESI)+: calcd for
C5H9
79BrN4NaO
+, 242.9852; found, 242.9852. The 1H NMR data
were in agreement with the data reported in the literature.62
2-Bromo-N-(3-[4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl]-
propyl)acetamide (6). CuSO4 (7 mg, 0.027 mmol) and sodium
ascorbate (10.8 mg, 0.055 mmol) were combined in 1 mL of H2O and
added to a solution of alkyne 11 (100 mg, 0.55 mmol), azide 5 (145
mg, 0.66 mmol), and TBTA (14.5 mg, 0.027 mmol) in DMSO (2
mL). The mixture was left to stir at 45 °C, and the reaction was
monitored by TLC. Once the reaction was complete (1.5 h), the
reaction mixture was filtered through Celite and washed with H2O,
and the filtrate was redissolved in DMF. The DMF was concentrated
to a minimum amount before EtOAc (30 mL) was added and the
organic phase was rapidly washed with EDTA in ammonium
hydroxide (1.0 M, 50 mL). The organic fraction was dried (MgSO4)
and filtered, and the remaining residue was purified by flash column
chromatography (90:10 EtOAc/MeOH). The product was isolated as
a white powder (0.04 g, 18%). Rf 0.36 (80:20 DCM/MeOH), mp
182−185 °C. 1H NMR (500 MHz, DMSO-d6): δH 8.70 (s, 1H,
triazole CH), 8.39 (t, 1H, NH), 8.02 (m, 2H, 2 × ArCH), 7.89 (m,
2H, 2 × ArCH), 7.37 (s, 2H, SO2NH2), 4.45 (t, J = 7.0 Hz, 2H,
εCH2), 3.85 (s, 2H, βCH2), 3.15 (q, J = 6.7 Hz, 2H, γCH2), 2.08−2.02
(quint, J = 6.9 Hz, 2H, δCH2).
13C NMR (500 MHz, DMSO-d6): δC
166.2 (αCO), 145.0 (Cq), 143.1 (triazole Cq), 133.9 (Cq), 126.4 (2
× CHAr), 125.3 (2 × CHAr), 122.6 (triazole CH), 47.4 (εCH2), 36.3
(γCH2), 29.5 (βCH2 and δCH2), 29.4 (βCH2 and δCH2). LRMS
(ESI−): m/z = 402, 400 [M − H; 81Br, 79Br]−. HRMS (ESI): calcd for
C13H16BrN5O3S
+, 402.0228; found, 402.0208.
Tri-tert-butyl 2,2′,2″-(10-(2-Oxo-2-((3-(4-(4-sulfamoylphenyl)-1H-
1,2,3-triazol-1-yl)propyl)amino)ethyl)-1,4,7,10-tetraazacyclodode-
cane-1,4,7-triyl)triacetate (8). Compound 7 (109 mg, 0.21 mmol), 6
(85 mg, 0.21 mmol), and K2CO3 (58 mg, 0.42 mmol) were dissolved
in anhydrous MeCN (5 mL), and the reaction mixture was stirred
overnight at room temperature. The mixture was filtered through
Celite and washed with MeOH. The residue was purified by flash
column chromatography (gradient 100% DCM→ 85:15 DCM/
MeOH). Appropriate fractions were combined, and the product was
isolated as a hygroscopic solid (59.3 mg, 33%). Rf 0.04 (95:5 DCM/
MeOH). 1H NMR (400 MHz, DMSO-d6, 85 °C): δH 8.63 (s, 1H, CH
triazole), 8.17 (t, J = 5.38 Hz, 1H, NH), 7.98 (m, 2H, 2 × ArCH), 7.91
(m, 2H, 2 × ArCH), 7.20 (s, 2H, SO2NH2), 4.45 (t, J = 7.1 Hz, 2H,
εCH2), 3.53 (MeOH), 3.19 (m, 2H, γCH2), 3.08 (s, 6H, τCH2), 2.94
(dt, J = 42.0, 5.2 Hz, 2H, CH2 Aza), 2.61 (br, 7H, CH2 Aza), 2.30 (br,
7H, CH2 Aza), 2.10 (quint, J = 6.9 Hz, 2H, δCH2), 1.44 (s, 9H, tBu),
1.40 (s, 18H, 2 × tBu). 13C NMR (75.5 MHz, DMSO-d6): δC 172.5
(CO), 172.2 (2 × CO), 171.6 (CO), 145.0 (Cq triazole),
143.1 (Cq Ar), 133.9 (Cq Ar), 126.4 (2 × ArCH), 125.3 (2 × ArCH),
122.5 (CH triazole), 81.1 (Cq tBu), 80.9 (2 × Cq tBu), 69.8 (MeOH),
60.18 (τCH2), 55.7 (τCH2), 55.3 (τCH2), 54−49 (CH2 Aza in
baseline), 47.6 (εCH2), 36.0 (γCH2), 29.6 (δCH2), 27.9 (βCH3), 27.5
(CH3 tBu). LRMS (ESI
+): m/z = 836 [M + H]+. HRMS (ESI): calcd
for C39H65N9NaO9S
+, 858.4518; found, 858.4513.
2,2′,2″-(10-(2-Oxo-2-((3-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-
1-yl)propyl)amino)ethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)triacetic Acid (9). Compound 8 (87.7 mg, 0.1 mmol) was
dissolved in 1:1 DCM/TFA (8 mL), and the solution was stirred at 40
°C for 3 h. The reaction progress was monitored by LC−MS and RP-
18 TLC. When conversion was complete, the solvent was removed in
vacuo and then coevaporated with water (×3) followed by
lyophilization. Rf 0.76 (50:50 MeOH/H2O RP-18 TLC). Samples
for radiolabeling were purified using HPLC (isocratic 7:93 MeCN/
H2O + 0.1% formic acid on a Waters Atlantis T3 C18 column (19 mm
Scheme 3. Atom Labeling of DOTA Compounds
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× 150 mm, 10 μM) at a flow rate of 12 mL/min). Product fractions
were collected, and the solvent was removed in vacuo (8.5 mg, 52%
HPLC recovery). 1H NMR (500 MHz, DMSO-d6): δH 8.69 (s, 1H,
CH triazole), 8.57 (t, J = 5.2 Hz, 1H, NH), 8.01 (m, 2H, 2 × ArCH),
7.90 (s, 2H, 2 × ArCH), 7.38 (s, 2H, SO2NH2), 4.48 (t, J = 6.8 Hz,
2H, εCH2), 4.1−3.0 (m, signals masked by broad H2O peak), 3.18 (q,
J = 5.1 Hz, 2H, γCH2), 2.08 (quint, 2H, δCH2). Correlations under
the H2O peak were observed in the
1H−1H gCOSY and HSQC
spectra. LRMS (ESI+): m/z = 668 [M + H]+. HRMS (ESI): calcd for
C27H42N9O9S
+, 668.2821; found, 668.2819.
N-[2-[2-[2-(2-Azidoethoxy)ethoxy]ethoxy]ethyl]-2-bromoaceta-
mide (11). The title compound was synthesized from 11-azido-3,6,9-
trioxaundecanamine (10) (450 mg, 2.08 mmol) using general
procedure 1 and isolated as a yellow oil (0.54 g, 76%). Rf 0.35
(95:5 DCM/MeOH). 1H NMR (500 MHz, CDCl3): δH 6.92 (s, 1H,
NH), 3.87 (s, 2H, βCH2), 3.71−3.63 (m, 10H, εCH2, ζCH2), 3.59 (t, J
= 5.1 Hz, 2H, δCH2), 3.49 (m, 2H, γCH2), 3.39 (t, J = 5.0 Hz, 2H,
ηCH2N3).
13C NMR (125 MHz, CDCl3): δC 165.8 (αCO), (70.9,
70.8, 70.7, 70.5, 70.2, εCH, ζCH2), 69.5 (δCH2), 50.8 (ηCH2), 40.1
(γCH2), 29.2 (βCH2). LRMS (ESI
−): m/z 339, 337 [M − H, 81Br,
79Br]−. HRMS (ESI+): calcd for C10H19
79BrN4O4
+, 339.0662; found,
339.0684. The 1H NMR data were in agreement with the data
reported in the literature.66
2-Bromo-N-[[2-(2-[2-[4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-1-
yl]ethoxy]ethoxy)ethoxy]methyl]acetamide (12). CuSO4 (2 mg,
0.007 mmol) and sodium ascorbate (14 mg, 0.071 mmol) were
combined in 1 mL of H2O and added to a solution of azide 11 (264
mg, 0.78 mmol), alkyne 5 (128 mg, 0.71 mmol), and TBTA (4 mg,
0.007 mmol) in DMSO (2 mL). The mixture was left to stir at 45 °C,
and the reaction was monitored by TLC. Once the reaction was
complete, the reaction mixture was diluted with H2O and EtOAc, and
the aqueous phase was extracted with EtOAc (4 × 30 mL). The
organic fractions were combined and washed with EDTA (1.0 M) in
ammonium hydroxide (28.0−30.0%, NH3 basis) solution, dried
(Na2SO4), filtered, and purified by flash column chromatography
(95:5 EtOAc/MeOH or DCM/MeOH). The product was isolated as a
yellow gum (0.148 g, 40%). Rf 0.2 (95:5 DCM/MeOH), mp 85−90
°C. 1H NMR (500 MHz, DMSO-d6): δH 8.66 (s, 1H, triazole CH),
8.28 (br t, J = 5.90 Hz, 1H, NH), 8.02 (m, 2H, 2 × ArCH), 7.90 (m,
2H, 2 × ArCH), 7.36 (s, 2H, SO2NH2), 4.60 (t, J = 5.2 Hz, 2H,
ηCH2), 3.88 (t, J = 5.2 Hz, 2H, ζCH2), 3.84 (s, 2H, βCH2), 3.58−3.45
(m, 8H, εCH2), 3.39 (t, J = 5.7 Hz, 2H, δCH2NH), 3.20 (q, J = 5.67
Hz, 2H, γCH2).
13C NMR (500 MHz, DMSO-d6): δC 166.0 (αCO),
144.9 (Cq Ar-triazole), 143.0 (Cq Ar-SO2NH2), 133.9 (Cq triazole),
126.3 (2 × ArCH), 125.25 (2 × ArCH), 122.84 (CH triazole), 69.7−
69.5 (εCH2, 4C), 68.7 (δCH2 or ζCH2), 68.6 (δCH2 or ζCH2), 54.8
(DCM), 49.7 (ηCH2), 48.6 (γCH2), 29.4 (βCH2). LRMS (ESI
+): m/z
= 544, 542 [M + Na, 81Br, 79Br]+; 522, 520 [M + H, 81Br, 79Br]+.






cyclododecane-1,4,7-triyl)triacetate (13). Compound 12 (0.196 g,
0.37 mmol), 7 (253 mg, 0.49 mmol), and K2CO3 (68 mg, 0.49 mmol)
were dissolved in anhydrous MeCN (8 mL), and the reaction mixture
was stirred at 60 °C for 3h. The mixture was filtered through Celite,
washed (MeCN), and concentrated, and the remaining residue was
purified by column chromatography (90:10 DCM/MeOH). The
fractions were monitored by HPLC, and positive fractions were
combined to give the title compound as a hygroscopic off-white solid
(0.268 g, 76%). Rf 0.28 (90:10 DCM/MeOH).
1H NMR (500 MHz,
DMSO-d6): δH 8.67 (s, 1H, CH triazole), 8.18 (t, J = 5.9 Hz, 1H,
NH), 8.02 (m, 2H, 2 × ArCH), 7.90 (m, 2H, 2 × ArCH), 7.37 (s, 2H,
SO2NH2), 4.59 (t, J = 5.1 Hz, 2H, ηCH2), 3.88 (t, J = 5.1 Hz, 2H,
ζCH2), 3.50 (m, 8H, εCH2), 3.41 (t, J = 5.94 Hz, 2H, δCH2), 3.21 (m,
2H, γCH2), 3.1−2.0 (br, m, 24H, Aza CH2, βCH2, 3 × τCH2), 1.43 (s,
9H, tBu), 1.41 (s, 18H, 2 × tBu). 13C NMR (125 MHz, DMSO-d6): δC
172.5 (CO), 172.1 (2 × CO), 171.6 (CO), 144.9 (Cq
triazole), 143.1 (Cq Ar), 134.0 (Cq Ar), 126.3 (2 × ArCH), 125.2 (2
× ArCH), 122.8 (CH triazole), 81.1 (Cq tBu), 80.9 (2 × Cq tBu),
69.6−69.5 (εCH2, βCH2), 68.8 (ζCH2), 68.5 (δCH2), 59.7 (τCH2),
55.7 (τCH2), 55.3 (τCH2), 49.7 (ηCH2), 38.5 (γCH2), 27.5 (CH3
tBu), CH2 Aza peaks masked in baseline. LRMS (ESI
+): m/z = 954 [M





methyl]-1,4,7,10-tetraazacyclododecan-1-yl]acetic Acid (14). Com-
pound 13 (0.219 mg, 0.23 mmol) was dissolved in formic acid or 1:1
TFA/DCM (10 mL), and the solution was stirred at 60 °C. The
reaction was monitored by HPLC. Upon completion, water (10 mL)
was added, and the solvent was removed in vacuo and then
coevaporated with water (×3) followed by lyophilization. The sample
was purified by reversed-phase column chromatography using a
gradient of 100% H2O → 95:5 MeOH/H2O, and the product was
isolated as a hygroscopic white gum (144 mg, 80%). Rf 0.53 (50:50
MeOH/H2O RP-18 TLC). Samples were further purified via HPLC
prior to radiolabeling (isocratic 10:90 MeCN/H2O + 0.1% formic acid
on a Waters Atlantis T3 C18 column (19 mm × 150 mm, 10 μm) at a
flow rate of 12 mL/min). The product fractions were collected, and
the solvent was removed in vacuo (19%). 1H NMR (500 MHz,
DMSO-d6): δH 8.67 (s, 1H, CH triazole), 8.17 (br, 1H, NH), 8.02 (m,
2H, 2 × ArCH), 7.90 (m, 2H, 2 × ArCH), 7.38 (s, 2H, SO2NH2), 4.60
(t, J = 5.0 Hz, 2H, ηCH2), 3.88 (t, J = 5.3 Hz, 2H, ζCH2), the
remaining signals were masked by the broad H2O peak. Correlations
were observed in the 1H−1H gCOSY and HSQC spectra. LRMS
(ESI+): m/z 786 [M + H]+. HRMS (ESI): calcd for
C32H51N9NaO12S
+, 808.3281; found, 808.3278.
2,2′,2″-(10-(2-Oxo-2-((3-(4-(4-sulfamoylphenyl)-1H-1,2,3-triazol-
1-yl)propyl)amino)ethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)triacetic Acid Gallium Complex (natGa-1). Compound 9 (48 mg,
0.071 mmol) was treated as per general procedure 2 to give the title
compound as a hygroscopic white solid. LRMS (ESI−): m/z = 734 [M





Complex (natGa-2). Compound 14 (50 mg, 0.064 mmol) was treated
as per general procedure 2 to give the title compound as a hygroscopic
white solid. Rf 0.65 (RP-18 TLC, 60:40 H2O/MeOH). LRMS (ESI
+):
m/z 852 [M + H]+. HRMS (ESI): calcd for C32H49GaN9O12S
+,
852.2472; found, 852.2460.
Cell Culture. Human MDA-MB-231 breast cancer cells (ATCC-
26) for toxicity studies were cultured in Roswell Park Memorial
Institute (RPMI) 1640 medium supplemented with 10% fetal bovine
serum (FBS), 100 units/mL penicillin, and 100 μg/mL streptomycin
at 37 °C and 5% CO2. Cells were seeded at 3 × 10
4 cells/well (200 μL,
RPMI-1640) and allowed to grow for 24 h before being exposed to the
compound of interest. Untreated cells were used as a control. HCT116
human colorectal carcinoma cells (ATCC CCL-247) stably expressing
a CA IX-targeting shRNA (shCA IX) or nontargeting shRNA (shNT)
construct established as described previously61 were routinely cultured
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% FBS at 37 °C.
Cell Proliferation Assay. Compounds were dissolved in RPMI
medium to a final concentration of 1 mM, and linear dilutions ranging
from 1 mM to 1 μM were carried out in culture medium. After 24 h of
treatment at 37 °C and 5% CO2, MTT (20 μL, 5 mg/mL) was added.
After 3 h, SDS (50 μL, 20% (w/v) SDS in 0.01 M HCl) was added,
and the plates were left overnight before being read by a SpectraMax
fluorescence plate reader (Molecular Devices) at 570 nm. Experiments
were performed in triplicate and, where possible, were repeated three
times. Values were determined using the GraphPad Prism software
(www.graphpad.com).
Radiolabeling. Radiolabeling with 67Ga. [67Ga]GaCl3 in 0.1 M
HCl was prepared from commercial [67Ga]citrate for injection
(Lantheus) via standard conversion methods.67 In an acid-washed
microcentrifuge tube, the DOTA complex (25 μL, 1 mM H2O) and
sodium acetate buffer (100 μL, 0.1 M, pH 4.3) were combined, and
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the solution was agitated. 67GaCl3 (18−21 MBq in 0.1 M HCl) was
added, and the solution was heated at 95 °C for 10 min using a solid-
state heating block. The sample was stirred via convection. Once the
reaction was complete, a sample (20 μL, ∼3 MBq) was analyzed by
HPLC, and the radiochemical purity was noted. The solutions were
purified by HPLC (Atlantis T3, 10 mm × 250 mm, 5 μm, flow rate 3
mL/min) or rapid reversed-phase C-18 SPE (washed with copious
amounts of H2O and compounds eluted in 50:50 EtOH/H2O).
Stability of [67Ga]-1 and [67Ga]-2 versus Human Serum. Human
serum (150 μL) was placed in a previously acid-washed 0.5 mL
microcentrifuge tube. To this was added 10× PBS concentrate (15
μL), water (60 μL), and the radiocomplex (75 μL in water, 0.24−0.28
MBq). The mixture was agitated via a bench vortex mixer and then
incubated at 37.5 °C for the course of the study. Aliquots (5−15 μL)
were injected onto a Phenomenex Biosep SEC-S 3000 column (300
mm × 7.8 mm i.d., 5 μm, pore size 290 Å) with a mobile phase of 50
mM sodium phosphate and 300 mM NaCl (pH 7.0, 0.2 μm filtered) at
1 mL/min on an HPLC system. Serum uptake was assessed as a
percentage of the total activity in the chromatogram.
Stability of [67Ga]-1 and [67Ga]-2 in Phosphate-Buffered Saline.
In a previously acid-washed 0.5 mL microcentrifuge tube, 10× PBS
concentrate (20 μL), water (160 μL), and the radiocomplex (20 μL in
water, 0.2−0.23 MBq) were combined. The solution was agitated and
then incubated at 37.5 °C for the course of the study. Aliquots (5−50
μL) were injected onto a Waters Atlantis T3 C18 column (150 mm ×
4.6 mm i.d., 3 μm) with a mobile phase of 16:84 MeCN/ammonium
formate buffer (120 mM, pH 4.43, 0.2 μm filtered) at 0.6 mL/min on a
HPLC system. Stability was assessed as a percentage of the parent
radiocomplex.
Radiolabeling with 68Ga. The reaction progress was monitored by
radio-HPLC equipped with an Inertsil ODS C18 column (5 μm, 4.6
mm × 250 mm) using a gradient method (100% H2O→ 100% MeCN
over 17 min, 1 mL/min). Sodium acetate or ammonium acetate buffer
(3 M, 400 μL, pH 4.3−4.5) was combined with ∼800 MBq of 68Ga in
aqueous HCl (0.6 M, ∼1.2 mL), which was eluted from an iThemba
1480 MBq 68Ge/68Ga generator. Compound 14 in H2O (40 μL, 1
mM) was added, and the solution was mixed by Eppendorf pipet (pH
∼4.5) and then heated at 99 °C for 10 min. Reaction mixtures were
analyzed by radio-HPLC, and the radiochemical purity was
consistently >95%. The specific activity of [68Ga]-2 at the time of
radiolabeling was ∼20 MBq/nmol (800 MBq/40 nmol). Small-animal
PET imaging studies with [68Ga]-2 were carried out between 1 and 2.5
h post radiolabeling of 14 → [68Ga]-2. No further purification was
carried out prior to imaging. Samples (∼3.7 MBq) were diluted in
0.9% saline solution prior to injection.
CA Inhibition Assay. An Applied Photophysics stopped-flow
instrument was used for assaying the CA-catalyzed CO2 hydration
activity.58 IC50 values were obtained from dose−response curves
working at seven different concentrations of test compound by
nonlinear least-squares fitting using GraphPad Prism; values represent
means of at least three different determinations as described
previously.39 The inhibition constants (Ki) were then derived using
the Cheng−Prusoff equation: Ki = IC50/(1 + [S]/Km), where [S] is the
CO2 concentration at which the measurement was carried out and Km
is the concentration of substrate at which the enzyme activity is half-
maximal. All of the enzymes used were recombinant, produced in
Escherichia coli as reported earlier.68,69 The following concentrations of
enzymes were used in the assay: hCA I, 10.4 nM; hCA II, 8.3 nM;
hCA IX, 8.0 nM; hCA XII, 12.4 nM.
Animal Model. Animal experiments were performed using adult
NMRI-nu mice. Animal facilities and experiments were in accordance
with local institutional guidelines for animal welfare and were
approved by the Maastricht University Animal Ethical Committee
(no. 2014-020). HCT116 cells stably expressing either a CA IX-
targeting shRNA (shCA IX) (n = 10) or CA IX-nontargeting shRNA
(shNT) (n = 10) construct established as described previously61 were
resuspended in BD Matrigel Basement Membrane Matrix (BD
Biosciences) and injected (106) subcutaneously into the lateral flank
of the animal.
Image Acquisition. Once tumors reached a volume between 180
and 300 mm3, animals were intravenously injected via the lateral tail
vein with ∼3.7 MBq of the 68Ga-labeled sulfonamide compound
diluted in 0.9% saline solution via an IV line flushed with 10% heparin
saline solution. For PET and CT scans, animals receiving only a PET
scan were anesthetized with isoflurane (induction 4%, maintenance 1−
2%); animals receiving both PET and CT scans were anesthetized with
an intraperitoneal injection of a 100 mg/kg ketamine/10 mg/kg
xylazine mixture. PET image acquisition was performed using a Focus
120 microPET (Siemens Medical Solutions USA, Inc.). Animals
receiving only a PET scan underwent a 9 min emission scan at 1, 2, 3,
and 4 h p.i., whereas animals receiving both PET and CT scans
underwent a 15 min emission scan 1 h p.i. The OSEM-3D-
reconstructed PET images were viewed and analyzed using the
PMOD software (PMOD Technologies Ltd.). Activity data (Bq/mL)
were obtained by manually delineating volumes of interest (VOIs) in
the PET images for mice that received only a PET scan or in the fused
PET/CT images for mice that received both PET and CT scans, using
the PMOD software. The tumor itself was delineated as tumor VOI
(T), whereas the heart outflow area was delineated as blood VOI (B).
Standardized uptake values (SUVs) were calculated by correcting the
activity data for the 68Ga injected dose, decay toward injection time,
and weight of the animal. Data were quantified by calculating the T/B
activity ratios (TBRs). CT image acquisition was performed using the
SmART system (X-RAD 225CX; Precision X-ray, North Branford,
CT, USA). Tumor volume at time of scanning was determined by
delineating the tumor on the CT image using the PMOD software.
Western Blot. Samples from tumors were minced, and proteins
were isolated using RIPA buffer completed with a protease inhibitor
cocktail (complete EDTA-free; Roche). Bradford assay (BioRad) was
performed for protein quantification. Proteins were separated on a
10% SDS-PAGE gel and blotted onto a nitrocellulose membrane (GE
Healthcare) by electrotransfer. Membranes were blocked in 5% nonfat
dry milk and probed overnight with mouse anti-CA IX monoclonal
antibody (M75, kindly provided by S. Pastorekova, Institute of
Virology, Slovak Academy of Science, Bratislava, Slovak Republic) and
mouse anti-β-actin monoclonal antibody (Cell Signaling). Subse-
quently, membranes were probed with horseradish peroxidase-linked
horse anti-mouse IgG antibodies (Cell Signaling), which were detected
with Western blot detection reagents (Thermo Fisher Scientific).
Immunofluorescence. Mice were injected intravenously with the
hypoxia marker pimonidazole 1 h before sacrifice. After sacrifice,
tumors were collected and sections were made. The sections were
fixed with cold acetone, and nonspecific binding was blocked using 1%
normal goat serum at room temperature for 30 min. The sections were
incubated overnight at 4 °C with rabbit anti-CA IX polyclonal
antibody (1:1000, Novus Biologicals) and fluorescein isothiocyanate-
conjugated mouse antipimonidazole monoclonal antibody (1:100,
Hypoxyprobe, Bioconnect). Subsequently, the sections were incubated
at room temperature for 1 h with Alexa Fluor 594-conjugated goat
anti-rabbit secondary antibody (1:500, Invitrogen). Mounting was
done using fluorescence mounting medium (Dako).
Autoradiography. Tumor sections (30 μm) were made using a
cyrotome (Leica) and placed on high-resolution phosphorimaging
plates (Storage Phosphor Screen BAS-IP SR 2040 E Super Resolution,
GE Healthcare) overnight. The plates were read using a Typhoon FLA
7000 laser scanner (GE Healthcare). Signal intensities were
determined using the ImageQuant TL software (GE Healthcare)
and normalized per animal to the respective ID.
Statistics. All of the statistical analyses were performed using
GraphPad Prism version 5.03. Unpaired Student’s t test was used to
determine the statistical significance of differences between two
independent groups of variables.
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